Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer

International Journal of Radiation Biology

Volumn 86, Issue 3, 2010, Pages 220-229

  Liu, Chunyan ^a   Zhang, Yonggang ^a   Liu, Minzhi Maggie ^a   Zhou, Haoming ^a   Chowdhury, Wasim ^a   Lupold, Shawn E ^a   Deweese, Ted L ^a   Rodriguez, Ronald ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute single high dose rate radiation; Adenocarcinoma of prostate; Continuous low dose rate radiation; Oncolytic viral therapy; Prostate specific conditionally replicative adenovirus; Radiosensitisation

Indexed keywords

ANDROGEN RECEPTOR; CONDITIONALLY REPLICATING ADENOVIRUS; GAMMA HISTONE H2AX; HISTONE H2AX; PHOSPHOPROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ARTICLE; CANCER RADIOTHERAPY; CELL DEATH; CELL NUCLEUS; CONTROLLED STUDY; CYTOTOXICITY; DOUBLE STRANDED DNA BREAK; ENHANCER REGION; HUMAN; HUMAN CELL; MALE; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; RADIATION DOSE; VIRUS REPLICATION;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANDROGEN-BINDING PROTEIN; ANIMALS; CELL DEATH; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, RADIATION; HISTONES; MALE; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RADIATION DOSAGE; RATS; RECEPTORS, ANDROGEN; TIME FACTORS; VIRUS REPLICATION;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; RATTUS;

EID: 77749295511     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.3109/09553000903419338     Document Type: Article

References (32)

1. Advani SJ, Mezhir JJ, Roizman B, Weichselbaum RR. 2006. ReVOLT: Radiation-enhanced viral oncolytic therapy. International Journal of Radiation Oncology Biology Physics 66:637-646.
2. Boyer J, Rohleder K, Ketner G. 1999. Adenovirus E4 34k and E4 11k inhibit double strand break repair and are physically associated with the cellular DNA-dependent protein kinase. Virology 263:307-312.
3. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. 2004. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10:33-39.
4. Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N, Lee J, Pennathur-Das R, Radzyminski J, Wypych J, Brignetti D, Scott S, Stephens J, Karpf DB, Henderson DR, Yu DC. 2001. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Research 61:5453-5460.
5. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. 2003. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Research 63:1550-1554.
6. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. 2004. The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management. Journal of Clinical Oncology 22:2141-2149.
7. DeWeese TL, Shipman JM, Dillehay LE, Nelson WG. 1998. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation exposure. Journal of Urology 159:591-598.
8. DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M, Hamper U, DeJong R, Detorie N, Rodriguez R, Haulk T, DeMarzo AM, Piantadosi S, Yu DC, Chen Y, Henderson DR, Carducci MA, Nelson WG, Simons JW. 2001. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Research 61:7464-7472.
9. Egami T, Ohuchida K, Mizumoto K, Onimaru M, Toma H, Nishio S, Nagai E, Matsumoto K, Nakamura T, Tanaka M. 2008. Radiation enhances adenoviral gene therapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake. Clinical Cancer Research 14:1859-1867.
10. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben RC. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Human Gene Therapy 9:1909-1917.
11. Freytag SO, Movsas B, Aref I, Stricker H, Peabody J, Pegg J, Zhang Y, Barton KN, Brown SL, Lu M, Savera A, Kim JH. 2007. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Molecular Therapy 15:1016-1023.
12. Hart LS, Ornelles D, Koumenis C. 2007. The adenoviral E4orf6 protein induces atypical apoptosis in response to DNA damage. Journal of Biological Chemistry 282:6061-6067.
13. Hart LS, Yannone SM, Naczki C, Orlando JS, Waters SB, Akman SA, Chen DJ, Ornelles D, Koumenis C. 2005. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. Journal of Biological Chemistry 280: 1474-1481.
14. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. 1998. A simplified system for generating recombinant adeno-viruses. Proceedings of the National Academy of Sciences of the USA 95:2509-2514.
15. Hoti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabul A, Hsieh JT, Berg M, Ketner G, Lupold SE, Rodriguez R. 2007. Androgen receptor attenuation of Ad5 replication: Implications for the development of conditionally replication competent adenoviruses. Molecular Therapy 15:1495-1503.
16. Idema S, Geldof AA, Dirven CM, van der Jagt M, Gerritsen WR, Vandertop WP, Lamfers ML. 2007. Evaluation of adenoviral oncolytic effect on glioma spheroids by 18F-DG positron-emission tomography. Oncology Research 16:471-477.
17. Lebedeva IV, Emdad L, Su ZZ, Gupta P, Sauane M, Sarkar D, Staudt MR, Liu SJ, Taher MM, Xiao R, Barral P, Lee SG, Wang D, Vozhilla N, Park ES, Chatman L, Boukerche H, Ramesh R, Inoue S, Chada S, Li R, De Pass AL, Mahasreshti PJ, Dmitriev IP, Curiel DT, Yacoub A, Grant S, Dent P, Senzer N, Nemunaitis JJ, Fisher PB. 2007. mda-7/IL-24, novel anticancer cytokine: Focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). International Journal of Oncology 31:985-1007.
18. Maggiorella L, Deutsch E, Frascogna V, Chavaudra N, Jeanson L, Milliat F, Eschwege F, Bourhis J. 2003. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Research 63:2513-2517.
19. Nagano S, Perentes JY, Jain RK, Boucher Y. 2008. Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. Cancer Research 68: 3795-3802.
20. Nguyen PL, Zietman AL. 2007. High-dose external beam radiation for localized prostate cancer: Current status and future challenges. Cancer Journal 13:295-301.
21. O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A, Boyle L, Pandey K, Soria C, Kunich J, Shen Y, Habets G, Ginzinger D, McCormick F. 2004. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 6:611-623.
22. Qian J, Yang J, Dragovic AF, Abu-Isa E, Lawrence TS, Zhang M. 2005. Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2. Cancer Research 65:5493-5497.
23. Querido E, Blanchette P, Yan Q, Kamura T, Morrison M, Boivin D, Kaelin WG, Conaway RC, Conaway JW, Branton PE. 2001a. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes & Development 15:3104-3117.
24. Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, Branton PE. 2001b. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. Journal of Virology 75:699-709.
25. Rajecki M, Kanerva A, Stenman UH, Tenhunen M, Kangasniemi L, Sarkioja M, Ala-Opas MY, Alfthan H, Sankila A, Rintala E, Desmond RA, Hakkarainen T, Hemminki A. 2007. Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Molecular Cancer Therapeutics 6:742-751.
26. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. 1997. Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research 57:2559-2563.
27. Shewach DS, Lawrence TS. 2007. Antimetabolite radiosensitizers. Journal of Clinical Oncology 25:4043-4050.
28. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. 2006. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Molecular Therapy 14:107-117.
29. Teh BS, Amosson CM, Mai WY, McGary J, Grant WH 3rd, Butler EB. 2004. Intensity modulated radiation therapy (IMRT) in the management of prostate cancer. Cancer Investigation 22:913-924.
30. van Beusechem VW, Grill J, Mastenbroek DC, Wickham TJ, Roelvink PW, Haisma HJ, Lamfers ML, Dirven CM, Pinedo HM, Gerritsen WR. 2002. Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished. Journal of Virology 76:2753-2762.
31. Wu L, Matherly J, Smallwood A, Adams JY, Billick E, Belldegrun A, Carey M. 2001. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Therapy 8:1416-1426.
32. Zegarra-Moro OL, Schmidt LJ, Huang H, Tindall DJ. 2002. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Research 62:1008-1013.